Literature DB >> 1412645

Is leishmaniasis ever cured?

R A de Rossell1, R J de Duran, O Rossell, A M Rodríguez.   

Abstract

The persistence of parasites in mice cured of Leishmania mexicana infection was investigated by using immunosuppressive drugs and checking for the reappearance of lesions. BALB/c (susceptible) and C57BL/6 (partially resistant) mice infected with 10(4) amastigotes were treated with either thermotherapy or meglumine antimonate and subsequently immunosuppressed with either cyclophosphamide or hydrocortisone. Immunosuppression by either method caused lesions to reappear in both strains of mice regardless of the treatment used to produce clinical cure. In both strains of mice the proportion of animals developing lesions after immunosuppression was greater in the mice cured by the drug. The relevance of these findings to human therapy is discussed.

Entities:  

Mesh:

Year:  1992        PMID: 1412645     DOI: 10.1016/0035-9203(92)90297-p

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  15 in total

1.  Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.

Authors:  Rafael de La Rosa; Juan A Pineda; Juan Delgado; Juan Macías; Francisco Morillas; José A Mira; Armando Sánchez-Quijano; Manuel Leal; Eduardo Lissen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

Review 3.  Infectious diseases.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  1994-02       Impact factor: 2.401

4.  Immunoblot analysis of Leishmania panamensis antigens in sera of patients with American cutaneous leishmaniasis.

Authors:  D M Isaza; M Restrepo; W Mosca
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

5.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

6.  Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity.

Authors:  C R Davies; E A Llanos-Cuentas; S D Pyke; C Dye
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

7.  Immunoblot analysis of the humoral immune response to Leishmania donovani polypeptides in cases of human visceral leishmaniasis: its usefulness in prognosis.

Authors:  Promod Kumar; Kalpana Pai; Kiran Tripathi; H P Pandey; Shyam Sundar
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

8.  Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host.

Authors:  T Aebischer; S F Moody; E Handman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

Review 9.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

10.  Presence of Leishmania braziliensis in blood samples from cured patients or at different stages of immunotherapy.

Authors:  P Guevara; E Rojas; N Gonzalez; J V Scorza; N Añez; M Valera; J L Ramírez
Journal:  Clin Diagn Lab Immunol       Date:  1994-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.